Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|
Return on Invested Capital (ROIC) | (1,848.4%) | (1,532.5%) | 1,576.5% | 629.3% | 3,943.9% | (787.2%) | (502.0%) | (985.7%) | (1,577.9%) | (1,480.3%) |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month Return on Invested Capital (ROIC) is 1,393.1%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Invested Capital (ROIC) for Protagonist Therapeutics, Inc. have been (1,400.3%) over the past three years, and (1,281.6%) over the past five years.
As of today, Protagonist Therapeutics, Inc.'s Return on Invested Capital (ROIC) is 1,393.1%, which is higher than industry median of (130.0%). It indicates that Protagonist Therapeutics, Inc.'s Return on Invested Capital (ROIC) is Good.